Renexxion and Dr. Falk Pharma Advance Naronapride into Phase 3 Targeting US NDA and EU Approval

Naronapride's progression into pivotal studies signals an imminent NDA filing strategy for Renexxion and Dr. Falk Pharma, placing GI drug manufacturers and regulatory affairs teams on notice that a harmonized US/EU submission framework is now in active construction. The move follows positive results from the 328-patient global Phase 2b MOVE-IT study (NCT05621811), evaluating naronapride in gastroparesis patients across multiple geographies.

Renexxion has confirmed it intends to use Phase 3 data to support a new drug application (NDA) with the FDA, while Dr. Falk Pharma leads the parallel European development track. The dual-jurisdiction structure means process validation, analytical method transfers, and CMC documentation will need to satisfy both 21 CFR Part 211 and EMA expectations simultaneously, a coordination burden that typically surfaces late and under-resourced in programs of this scale.

Naronapride is an oral, locally acting pan-GI prokinetic operating through a dual mechanism: 5-HT4 receptor agonism and dopamine D2 receptor antagonism. Its minimal systemic bioavailability is a defining pharmacokinetic feature, and one that will shape sterility assurance and formulation development decisions as the program scales toward commercial manufacturing. The compound has accumulated safety data across nine Phase 1 and five Phase 2 trials in indications including gastroesophageal reflux disease and chronic idiopathic constipation.

The gastroparesis indication carries particular regulatory weight. Approximately 22 per 100,000 individuals in the US and Europe carry a formal diagnosis, with symptomatic prevalence estimated at up to 12 times that figure. Available long-term treatment options remain limited, a gap the FDA has historically treated as a factor in expedited review eligibility assessments. Regulatory affairs leads tracking the NDA timeline should note that the Phase 3 design will need to align with FDA's gastroparesis endpoint guidance, which has evolved considerably over recent review cycles.

For QA directors and plant heads, the manufacturing readiness question is straightforward: a globally harmonized pivotal program compresses the window between Phase 3 lock and NDA submission, leaving less margin for late-stage process validation gaps or comparability failures across sites. Dr. Falk Pharma's six-decade GI manufacturing heritage provides a baseline, but the cross-border CMC alignment required for concurrent US and EU filings demands early engagement between both parties' quality systems under ICH Q10 principles.

The measurable checkpoint ahead is Phase 3 enrollment completion and the dataset that will anchor Renexxion's NDA package, the quality of that submission will determine whether the harmonized development strategy delivers on its regulatory efficiency premise.

Source: GlobeNewswire via Dr. Falk Pharma / Renexxion press release, 1 June 2026.